Angle PLC Announces Rapid Information on Patient Response to Therapies

Rhea-AI Summary

ANGLE plc has announced promising research results from the University of Maryland regarding its Parsortix system for liquid biopsy. The study, focusing on triple-negative breast cancer (TNBC), demonstrated that the isolation of live circulating tumor cells (CTCs) can provide quick insights into patient responses to therapies targeting metastasis. Notably, vinorelbine treatment improved the time to cancer spread significantly. As TNBC cases continue to rise, this research could enhance treatment options and offer rapid, actionable insights for patients facing limited therapies.

Positive

• Parsortix system shows potential for rapid assessment of patient response to therapies.
• Vinorelbine treatment increased the time for cancer spread from 8 to 30 weeks.
• Research addresses the urgent need for improved TNBC treatment options.

Negative

• Vinorelbine treatment had little effect on primary tumor development and survival.

PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS

• Existing chemotherapies, such as vinorelbine, may selectively target and reduce the metastatic potential of CTCs
• Detecting a reduction of microtentacles, that enable the spread of cancer, on live CTCs indicates a positive response to therapy

GUILDFORD, UK / ACCESSWIRE / March 29, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, has published results of work undertaken in preclinical models of triple-negative breast cancer (TNBC), showing that isolation of live circulating tumour cells (CTCs) from a simple blood draw, using the Parsortix^® system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth.

The research team has previously demonstrated that breast cancer cells circulating in the blood form unique microtentacles that enable the spread and formation of tumours at secondary sites. Microtentacles are supported by microtubules, which are the target for many FDA-approved chemotherapy drugs, such as vinorelbine used in this study.

Using preclinical TNBC models, the researchers showed that vinorelbine treatment increased the time taken for the cancer to spread from 8 to 30 weeks. However, a 24-hour vinorelbine treatment had little effect on the primary tumour development and survival, indicating selective targeting of the metastatic potential of CTCs through microtubule disruption. The results of this study indicate that CTCs demonstrate specific features which can be leveraged to reveal the anti-metastatic capabilities of vinorelbine and potentially other existing FDA-approved therapies.

In the US, breast cancer is the most frequently diagnosed cancer in women with 287,000 new cases expected in 2022, accounting for 31% of all new cancer cases. The American Cancer Society estimates that TNBC accounts for about 10-15% of all breast cancers. TNBC differs from other types of invasive breast cancer in that it grows and spreads faster, has limited treatment choices, and a worse prognosis. TNBC patients are recommended for chemotherapy treatments, due to lack of targeted therapies, yet some pre-clinical studies have shown that neoadjuvant chemotherapy can increase the risk of metastasis. There is an urgent need to improve treatment options for patients with early stage TNBC that can reduce the metastatic risk.

Prof Stuart Martin, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, commented:
"Cancer drugs that broadly disrupt microtubules have long proven effective at reducing tumor growth and improving patient survival, but also have significant toxicities that limit dosing. The focused treatment reported here reduced microtentacles and metastasis at well below the maximum-tolerated dose. If it is possible to use a focused treatment to reduce CTC metastasis, the most likely opportunity for therapies to reduce CTC metastasis would be combination therapy at the time of primary tumor treatment, helping to ensure that CTCs shed by that primary tumor treatment have reduced metastatic potential".

ANGLE Founder and Chief Executive, Andrew Newland, added:
"We are pleased to report on the use of the Parsortix system for the isolation of live CTCs in pre-clinical TNBC models, uncovering the potential to provide rapid information on how a patient is responding to a therapy. ANGLE's ability to provide actionable insight could help patients with limited treatment options and could help to identify already approved drugs that could target highly metastatic and hard-to-treat cancers, such as TNBC."

The research has been published as a peer-reviewed publication in the journal Breast Cancer Research and is available online at https://angleplc.com/library/publications/.

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker) Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave	+44 (0) 20 3207 7800
Jefferies (Joint Broker) Max Jones, Thomas Bective	+44 (0) 20 7029 8000
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix^® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis and may provide comparable analysis to a tissue biopsy. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

The Parsortix system has a CE Mark in Europe for the indicated use and, in the United States, a De Novo Submission has been made to FDA for the Parsortix^® PC1 system seeking FDA clearance with Class II Classification for use with metastatic breast cancer patients. FDA clearance is seen as the global standard. ANGLE is seeking to be the first ever FDA cleared system for harvesting CTCs for subsequent analysis.

ANGLE has also completed two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation and a 200 patient clinical verification study has now completed enrolment.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEAD^TM platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 58 peer-reviewed publications and numerous publicly available posters, available on our website.

ANGLE has established clinical services laboratories in the UK and USA to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View source version on accesswire.com:
https://www.accesswire.com/695042/Angle-PLC-Announces-Rapid-Information-on-Patient-Response-to-Therapies

FAQ

What are the findings of the ANGLE plc press release regarding the Parsortix system and TNBC?

ANGLE plc announced that the Parsortix system can isolate live circulating tumor cells (CTCs) to provide rapid insights into patient response to therapies, with significant results from vinorelbine treatment in preclinical models.

How does the Parsortix system benefit patients with triple-negative breast cancer (TNBC)?

The Parsortix system offers rapid information on patient responses to existing chemotherapy treatments, potentially improving outcomes for TNBC patients who often face limited therapy options.

What impact did vinorelbine have on the metastatic potential of TNBC in the study mentioned by ANGLE plc?

Vinorelbine treatment significantly increased the time taken for TNBC to spread from 8 weeks to 30 weeks, demonstrating its selective targeting of CTCs.

What is the significance of the microtentacles in CTCs in the context of cancer metastasis?

Microtentacles on CTCs are involved in the spread of cancer, and their reduction indicates a positive response to therapy, as confirmed by the research using vinorelbine.

What does the research published by ANGLE plc suggest about existing chemotherapy drugs?

The research suggests that existing chemotherapy drugs, like vinorelbine, can be effective in targeting the metastatic potential of CTCs, offering insights for future cancer treatment strategies.